Matrix metalloproteinases in cancer: comparison of known and novel aspects of their inhibition as a therapeutic approach

References

• McLeod HL. Individualized cancer therapy: molecular approaches to the prediction of tumor response. Expert Rev. Anticancer Ther.2, 113–119 (2002).
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell100, 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Hagedorn HG, Bachmeier BE, Nerlich AG. Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-α in invasive carcinomas. Int. J. Oncol.18, 669–681 (2001).
   PubMedGoogle Scholar
• DeClerck YA, Mercurio AM, Stack MS et al. Proteases, extracellular matrix and cancer. Am. J. Pathol.164, 1131–1139 (2004).
   PubMed Web of Science ®Google Scholar
• Overall C, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Rev. Cancer2, 657–672 (2002).
   PubMed Web of Science ®Google Scholar
• Borkakoti N. Matrix metalloprotease inhibitors: design from structure. Biochem. Soc. Trans.32, 17–20 (2004).
   PubMedGoogle Scholar
• Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci.115, 3719–3727 (2002).
   PubMed Web of Science ®Google Scholar
• Brown PD. Matrix metalloproteinase inhibitors. Angiogenesis1, 142–154 (1997).
   Google Scholar
• Ramnath N, Creaven PJ. Matrix metalloproteinase inhibitors. Curr. Oncol. Rep.6, 96–102 (2004).
   PubMedGoogle Scholar
• Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br. J. Cancer89, 1817–1821 (2003).
   PubMed Web of Science ®Google Scholar
• Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biological activity and clinical implications. J. Clin. Oncol.18, 1135–1149 (2000).
   PubMed Web of Science ®Google Scholar
• Westermarck J, Kähäri VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J.13, 781–792 (1999).
   PubMed Web of Science ®Google Scholar
• Woessner JF. The matrix metalloproteinase family. In: Matrix Metalloproteinases. Parks WC, Meachim RP (Eds), Academic Press, CA, USA. 1–14 (1998).
   Google Scholar
• Seltzer JL, Eisen AZ, Bauer EA et al. Cleavage of Type VII collagen by interstitial collagenase and Type IV collagenase (gelatinase) derived from human skin. J. Biol. Chem.164, 3822–3826 (1989).
   Google Scholar
• Hasty KA, Jeffrey JJ, Hibbs MS, Welgus HG. The collagen substrate specificity of human neutrophil collagenase. J. Biol. Chem.262, 10048–10052 (1987).
   PubMed Web of Science ®Google Scholar
• Goldberg GI, Wilhelm S, Kronberger A et al. Human fibroblast collagenase. Complete primary structure and homology to an oncogene transformation-induced rat protein. J. Biol. Chem.261, 6600–6605 (1986).
   PubMed Web of Science ®Google Scholar
• Bachmeier BE, Nerlich AG, Boukamp P et al. Human keratinocyte cell lines differ inthe expression of the collagenolytic matrix metalloproteinases-1, -8, and -13 and TIMP-1. Biol. Chem.381, 509–516 (2000).
   PubMed Web of Science ®Google Scholar
• Bode W, Maskos K. Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. Biol. Chem.384, 863–872 (2003).
   PubMed Web of Science ®Google Scholar
• Barrett AJ, Rawlings ND, Woessner JF. Handbook of Proteolytic Enzymes. Academic Press, London, UK (1998).
   Google Scholar
• Yoon SO, Park SJ, Yun CH, Chung AS. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J. Biochem. Mol. Biol.36(1), 128–137 (2003).
   PubMedGoogle Scholar
• Shapiro SD, Kobayashi DK, Ley TJ. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J. Biol. Chem.268, 23824–23829 (1993).
   PubMed Web of Science ®Google Scholar
• Shipley JM, Wesselschmidt RL, Kobayashi DK et al. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc. Natl Acad. Sci. USA93, 3942–3946 (1996).
   PubMed Web of Science ®Google Scholar
• Marchenko GN, Strongin AY. MMP-28, a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors. Gene265, 87–93 (2001).
   PubMed Web of Science ®Google Scholar
• Saarialho-Kere U, Kerkela E, Jahkola T et al. Epilysin (MMP-28) expression is associated with cell proliferation during epithelial repair. J. Invest. Dermatol.119, 14–21 (2002).
   PubMed Web of Science ®Google Scholar
• Chakraborti S, Mandal M, Das S et al. Regulation of matrix metalloproteinases: an overview. Mol. Cell. Biochem.253, 269–285 (2003).
   PubMed Web of Science ®Google Scholar
• Bannikov GA, Karelina TV, Collier IE et al. Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptides. J. Biol. Chem.277, 16022–16027 (2002).
   PubMed Web of Science ®Google Scholar
• Overall CM, Tam E, McQuibban GA et al. Domain interactions in the gelatinase A:TIMP-2:MT1-MMP activation complex: the ectodomain of the 44 kDa form of membrane Type 1 matrix metalloproteinase does not modulate gelatinase A activation. J. Biol. Chem.275, 39497–39505 (2000).
   PubMedGoogle Scholar
• Deryugina EI, Ratnikov B, Monosov E et al. MT1-MMP initiates activation of pro-MMP-2 and integrin ανα3 promotes maturation of MMP-2 in breast carcinoma cells. Exp. Cell Res.263, 209–223 (2001).
   PubMed Web of Science ®Google Scholar
• Seiki M. Membrane-type matrix metalloproteinases. APMIS107, 137–143 (1999).
   PubMed Web of Science ®Google Scholar
• Basset P, Okada A, Chenard MP et al. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol.15, 535–541 (1997).
   PubMed Web of Science ®Google Scholar
• Johnsen M, Lund LR, Romer J, Almholt K, Dano K. Cancer invasion and tissue remodelling: common themes in proteolytic matrix degradation. Curr. Opin. Cell Biol.10, 667–671 (1998).
   PubMed Web of Science ®Google Scholar
• Bachmeier BE, Boukamp P, Lichtinghagen R, Fusenig N, Fink E. Matrix metalloproteinase-2, -3, -7, -9 and -10, but not -11 are differentially expressed in normal, benign and malignant human keratinocyte cell lines. Biol. Chem.381, 497–507 (2000).
   PubMedGoogle Scholar
• Bachmeier BE, Nerlich A, Lichtinghagen R, Sommerhoff CP. Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity. Anticancer Res.21, 3821–3828 (2001).
   PubMed Web of Science ®Google Scholar
• Lebeau A, Nerlich AG, Sauer U, Lichtinghagen R, Löhrs U. Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas. Anticancer Res.19, 4257–4264 (1999).
   PubMedGoogle Scholar
• Lebeau A, Müller-Aufdemkamp C, Allmacher C et al. Cellular protein and mRNA expression patterns of matrix metalloproteinases-2, -3 and -9 in human breast cancer: correlation with tumor growth. J. Mol. Histol.35(5),443–455 (2004).
   PubMedGoogle Scholar
• Nerlich AG, Lebeau A, Hagedorn HG, Sauer U, Schleicher ED. Morphological aspects of altered basement membrane metabolism in invasive carcinomas of the breast and the larynx. Anticancer Res.18, 3515–3520 (1998).
   PubMed Web of Science ®Google Scholar
• O’Charoenrat P, Rhys-Evans PH, Eccles SA. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg.127, 813–820 (2001).
   PubMedGoogle Scholar
• Fundyler O, Khanna M, Smoller BR. Metalloproteinase-2 expression correlates with aggressiveness of cutaneous squamous cell carcinomas. Mod. Pathol.17, 496–502 (2004).
   PubMedGoogle Scholar
• Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinase: evolution, structures and function. Biochim. Biophys. Acta1477, 267–283 (2000).
   PubMed Web of Science ®Google Scholar
• Will H, Atkinson SJ, Butler GS, Smith B, Murphy G. The soluble catalytic domain of membrane Type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation: regulation by TIMP-2 and TIMP-3. J. Biol. Chem.271, 17119–17123 (1996).
   PubMed Web of Science ®Google Scholar
• Amour A, Knight CG, Webster A et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett.473, 275–279 (2000).
   PubMed Web of Science ®Google Scholar
• Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J. Biol. Chem.276, 12501–12504 (2001).
   PubMed Web of Science ®Google Scholar
• Yu WH, Yu S, Meng Q, Brew K, Woessner JF. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J. Biol. Chem.275, 31226–31232 (2000).
   PubMed Web of Science ®Google Scholar
• Visser R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function and biochemistry. Circ. Res.92, 827–839 (2003).
   PubMedGoogle Scholar
• Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumor growth and invasion. Ann. Med.31, 34–45 (1999).
   PubMed Web of Science ®Google Scholar
• Benaud C, Dickson RB, Thompson EW. Roles of matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res. Treat.50, 97–116 (1998).
   PubMed Web of Science ®Google Scholar
• Höyhtyä M, Fridman R, Komarek D et al. Immunohistochemical localization of matrix metalloproteinase-2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int. J. Cancer56, 500–505 (1994).
   PubMedGoogle Scholar
• Poulsom R, Hanby AM, Pignatelli M et al. Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J. Clin. Pathol.46, 429–436 (1993).
   PubMedGoogle Scholar
• Lee MH, Maskos K, Knäuper V, Dodds P, Murphy G. Mapping and characterization of the functional epitopes of tissue inhibitor of metalloproteinases (TIMP)-3 using TIMP-1 as the scaffold: a new frontier in TIMP engineering. Protein Sci.11, 2493–2503 (2002).
   PubMed Web of Science ®Google Scholar
• Lee MH, Rapti M, Knäuper V, Murphy G. Threonin 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition. J. Biol. Chem.279, 17562–17569 (2004).
   PubMed Web of Science ®Google Scholar
• Grignon DJ, Sakr W, Ravery V et al. High levels of tissue inhibitors of metalloproteinase 2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res.56, 1654–1659 (1996).
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson M, Mansoor A, Lim MS et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases (TIMPs) in reactive and neoplastic lymph nodes. Blood89, 1708–1715 (1997).
   PubMed Web of Science ®Google Scholar
• Brand K, Baker A, Perez-Canto A et al. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinase-2 into the liver tissue. Cancer Res.60, 5723–5730 (2000).
   PubMed Web of Science ®Google Scholar
• Celiker M, Wang M, Atsidaftos E et al. Inhibition of Wilm’s tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA. Oncogene20, 4337–4343 (2001).
   PubMed Web of Science ®Google Scholar
• Bergers G, Javaherian K, Lo K, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science284, 808–812 (1999).
   PubMed Web of Science ®Google Scholar
• Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science295, 2387–2392 (2002).
   PubMed Web of Science ®Google Scholar
• Jiang Y, Wang M, Celiker M et al. Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase-4 gene delivery. Cancer Res.61, 2365–2370 (2001).
   PubMed Web of Science ®Google Scholar
• Barrett AJ. α2-macroglobulin. Methods Enzymol.80, 737–754 (1981).
   PubMed Web of Science ®Google Scholar
• Cawston TE, Mercer E. Preferential binding of collagenase to α2-macroglobulin in the presence of the tissue inhibitor of metalloproteinases. FEBS Lett.209, 9–12 (1986).
   PubMed Web of Science ®Google Scholar
• Bein K, Simons M. Thrombospondin Type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J. Biol. Chem.275, 32167–32173 (2000).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Manzaneque JC, Lane TF, Ortega MA et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl Acad. Sci USA98, 12485–12490 (2001).
   PubMed Web of Science ®Google Scholar
• Takahashi C, Sheng Z, Horan T et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc. Natl Acad. Sci. USA95, 13221–13226 (1998).
   PubMed Web of Science ®Google Scholar
• Oh J, Takahasi R, Kondo S et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell107, 789–800 (2001).
   PubMed Web of Science ®Google Scholar
• Herman MP, Suhkova GK, Kisiel W et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J. Clin. Invest.107, 1117–1126 (2001).
   PubMed Web of Science ®Google Scholar
• Mott JD, Thomas CL, Rosenbach MT et al. Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinase inhibitor. J. Biol. Chem.275, 1384–1390 (2000).
   PubMedGoogle Scholar
• Woessner JF Jr. MMPs and TIMPs – an historical perspective. Mol. Biotechnol.22, 333–349 (2002).
   Google Scholar
• Beckett RP. Recent advances in the field of matrix metalloproteinase inhibitors. Expert Opin. Ther. Patents6, 1305–1315 (1996).
   Google Scholar
• Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of antitumor activity. Ann. Oncol.6, 967–974 (1995).
   PubMed Web of Science ®Google Scholar
• Tremont-Lukas IW, Gilbert MR. Advances in molecular therapies in patients with brain tumors. Cancer Control10, 125–137 (2003).
   PubMedGoogle Scholar
• Eskens FALM, Levitt NC, Sparreboom A et al. Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor. Clin. Cancer Res.6, 431–434 (2000).
   PubMedGoogle Scholar
• Levitt NC, Eskens FALM, O’Byrne KJ et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor MMI270 (CGS 27023A) in patients with advanced solid cancer. Clin. Cancer Res.7, 1912–1922 (2001).
   PubMed Web of Science ®Google Scholar
• Nakamura ES, Kiozumi K, Kobayashi M, Saiki I. Inhibition of lymphangiogenesis-related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270. Cancer Sci.95, 23–31 (2004).
   Google Scholar
• Sparano JA, Gray R, Giantonio B et al. Evaluating anti-angiogenesis agents in the clinic: the Eastern Co-operative Oncology Group portfolio of clinical trials. Clin. Cancer Res.10, 1206–1211 (2004).
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Adachi Y, Itoh F et al. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res.59, 3313–3316 (1999).
   PubMed Web of Science ®Google Scholar
• Murray GI, Duncan ME, O’Neil P et al. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature Med.4, 461–462 (1996).
   Google Scholar
• Yamamoto H, Itoh F, Iku S et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinoma: clinicopathologic and prognostic significance of matrilysin expression. J. Clin. Oncol.19, 1118–1127 (2001).
   PubMedGoogle Scholar
• Shepherd FA, Giaccone G, Seymour L et al. Prospective, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J. Clin. Oncol.20, 4434–4439 (2002).
   PubMed Web of Science ®Google Scholar
• Bramhall SR, Hallissey MT, Whiting J et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer86, 1864–1870 (2002).
   PubMed Web of Science ®Google Scholar
• Wall L, Talbot DC, Bradbury P, Jodrell DI. A Phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours. Br. J. Cancer90, 800–804 (2004).
   PubMed Web of Science ®Google Scholar
• Quirt I, Bodurth A, Lohmann R et al. Phase II study of marimastat (BB-2516) in malignant melanoma: clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest. New Drugs20, 431–437 (2002).
   PubMed Web of Science ®Google Scholar
• Larson DA, Prados M, Lamborn KR et al. Phase II study of high central dose gamma knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int. J. Radiat. Biol. Phys.54, 1397–1404 (2002).
   PubMed Web of Science ®Google Scholar
• Maekawa K, Sato H, Furukawa M, Yoshizaki T. Inhibition of cervical lymph node metastasis by marimastat (BB-2516) in an orthotopic oral squamous cell carcinoma implantation model. Clin. Exp. Metastasis19, 513–518 (2002).
   PubMed Web of Science ®Google Scholar
• Groves MD, Puduvalli VK, Hess KR et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor marimastat in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol.20, 1383–1388 (2002).
   PubMed Web of Science ®Google Scholar
• Bramhall SR, Schulz J, Nemunaitis J et al. A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer87, 161–167 (2002).
   PubMed Web of Science ®Google Scholar
• King J, Zhao J, Clingan P, Morris D. Randomised double-blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side effects. Anticancer Res.23, 639–645 (2003).
   PubMed Web of Science ®Google Scholar
• Uria JA, Lopez-Otin C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res.60, 4745–4751 (2000).
   PubMed Web of Science ®Google Scholar
• Pahl HL. Activators and target genes of Rel/NFκB transcription factors. Oncogene18, 6853–6866 (1999).
   PubMed Web of Science ®Google Scholar
• Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene20, 2390–2400 (2001).
   PubMed Web of Science ®Google Scholar
• Kondraganti S, Mohanam S, Chintala SK et al. Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res.60, 6851–6855 (2000).
   PubMed Web of Science ®Google Scholar
• Nagavarapu U, Relloma K, Herron GS. Membrane Type 1 matrix metalloproteinase regulates cellular invasiveness and survival in cutaneous epidermal cells. J. Invest. Dermatol.118, 573–581 (2002).
   PubMedGoogle Scholar
• Ala-Aho R, Grenman R, Seth P, Kähäri VM. Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous cells. Oncogene21, 1187–1195 (2000).
   Google Scholar
• Ma Z, Qin H, Benveniste EN. Transcriptional suppression of matrix metalloproteinase-9 expression by IFN-γ and IFN-α: critical role of STAT-1α. J. Immunol.167, 5150–5159 (2001).
   PubMed Web of Science ®Google Scholar
• Slaton JW, Karashima T, Perrotte P et al. Treatment with low-dose interferon-α restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin. Cancer Res.7, 2840–2853 (2001).
   PubMed Web of Science ®Google Scholar
• Mengshol JA, Mix KS, Brinckerhoff CE. Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull’s-eye or missing the mark? Arthritis Rheum.46, 13–20 (2002).
   PubMed Web of Science ®Google Scholar
• Lal A, Glazer CA, Martinson HM et al. Mutant epidermal growth factor receptor upregulates molecular effectors of tumor invasion. Cancer Res.62, 3335–3339 (2002).
   PubMed Web of Science ®Google Scholar
• Overall CM, Wrana JL, Sodeck J. Independent regulation of collagenase 72 kDa-progelatinase and metalloproteinase inhibitor expression in human fibroblasts by transforming growth factor α. J. Biol. Chem.264, 1860–1869 (1989).
   PubMed Web of Science ®Google Scholar
• Uria JA, Jimenez MG, Balbin M, Freije JMP, Lopez-Otin C. Differential effects of transforming growth factor α on the expression of collagenase-1 and collagenase-3 in human fibroblasts. J. Biol. Chem.273, 9769–9777 (1998).
   PubMed Web of Science ®Google Scholar
• Muraoka RS, Dumont N, Ritter CA et al. Blockade of TGF-α inhibits mammary tumor cell viability, migration and metastases. J. Clin. Invest.109, 1551–1559 (2002).
   PubMed Web of Science ®Google Scholar
• McGaha TL, Phelps RG, Spiera H, Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming growth factor-α-mediated Smad3 activation in fibroblasts. J. Invest. Dermatol.118, 461–470 (2002).
   PubMed Web of Science ®Google Scholar
• Shin M, Yan C, Boyd D. An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-jun activation, DNA-binding and PMA-inducible 92 kDa Type IV collagenase expression. Biochim. Biophys. Acta1589, 311–316 (2002).
   PubMed Web of Science ®Google Scholar
• Futamura M, Kamiya S, Tsukamoto M et al. Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells. Oncogene20, 6724–6730 (2001).
   PubMedGoogle Scholar
• Zhang Y, Thant AA, Machida K et al. Hyaluronan-CD44s signaling regulates matrix metalloproteinase-2 secretion in a human lung carcinoma cell line QG90. Cancer Res.62, 3962–3965 (2002).
   PubMed Web of Science ®Google Scholar
• Sato T, Koike L, Miyta Y et al. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinase-1 production and suppression of production of matrix metalloproteinase-1 and -9 in human fibrosarcoma HT-1080 cells. Cancer Res.62, 1025–1029 (2002).
   PubMed Web of Science ®Google Scholar
• Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr. Cancer21, 113–131 (1994).
   PubMed Web of Science ®Google Scholar
• Fotis T, Pepper M, Adlercreutz H et al. Genistein, a dietary ingestional isoflavonoid, inhibits cell proliferation and in vivo angiogenesis. J. Nutr.125, 790–797 (1995).
   Google Scholar
• Myoung H, Hong SP, Yun PY, Lee JU, Kim MJ. Anticancer effect of genistein in oral squamous cell carcinoma with respect to angiogenesis and in vitro invasion. Cancer Sci.94, 215–220 (2003).
   PubMed Web of Science ®Google Scholar
• Mukhtar H, Ahmad N. Tea polyphenols: prevention of cancer and optimizing health. Am. J. Clin. Nutr.71, 1698S–1702S (2000).
   PubMed Web of Science ®Google Scholar
• Oku N, Matsukawa M, Yamakawa et al. Inhibitory effect of green tea polyphenols on membrane-type 1 matrix metalloproteinase, MT1-MMP. Biol. Pharm. Bull.26, 1235–1238 (2003).
   PubMed Web of Science ®Google Scholar
• Garbisa S, Sartor L, Biggin S et al. Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer91, 822–832 (2001).
   PubMed Web of Science ®Google Scholar
• Demeule M, Brossard M, Page M et al. Matrix metalloproteinase inhibition by green tea catechins. Biochim. Biophys. Acta1478, 51–60 (2000).
   PubMed Web of Science ®Google Scholar
• Gupta S, Ahmad N, Nieminen AL, Mukhtar H. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol. Appl. Pharmacol.164, 82–90 (2000).
   PubMed Web of Science ®Google Scholar
• Ahmad N, Cheng P, Mukhtar H. Cell cycle dysregulation by green tea polyphenol epigallocatechin-3-gallate. Biochim. Biophys. Res. Commun.275, 328–334 (2000).
   PubMed Web of Science ®Google Scholar
• Lin JK, Liang YC, Lin-Shiau SY. Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Biochem. Pharmacol.58, 911–915 (1999).
   PubMed Web of Science ®Google Scholar
• Mohandas KM, Desai DC. Epidemiology of digestive tract cancers in India. Ind. J. Gastroenterol.18, 118–121 (1999).
   PubMedGoogle Scholar
• Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res.23, 363–398 (2003).
   PubMed Web of Science ®Google Scholar
• Thaloor D, Singh AK, Sidhu GS et al. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. Cell Growth Differ.9, 305–312 (1998).
   PubMedGoogle Scholar
• Okashi Y, Tsuchiya Y, Koizumi K, Sakurai H, Saiki I. Prevention of intrahepatic metastasis by curcumin in an orthotopic implantation model. Oncology65, 250–258 (2003).
   PubMedGoogle Scholar
• Shao ZM, Shen ZZ, Liu CH et al. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int. J. Cancer98, 234–240 (2002).
   PubMed Web of Science ®Google Scholar
• Santibanez JF, Quintanilla M, Martinez J. Genistein and curcumin block TGF-α 1-induced u-PA expression and migratory and invasive phenotype in mouse epidermal keratinocytes. Nutr. Cancer37, 49–54 (2000).
   PubMed Web of Science ®Google Scholar
• Wartenberg M, Budde P, De Marees M et al. Inhibition of tumor-induced angiogenesis and matrix metalloproteinase expression in confrontation cultures of embryoid bodies and tumor spheroids by plant ingredients used in traditional chinese medicine. Lab. Invest.83, 87–98 (2003).
   PubMed Web of Science ®Google Scholar